Drugs / HMB002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06754852 | Feb 2025 → Jul 2027 expected | von Willebrand disease 1, von Willebrand disease 2, von Willebrand disease 3 | Hemab ApS | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05491135 | Sep 2022 → Nov 2025 | acute liver failure | King's College Hospital NHS Trust | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HMB-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06754852 ↗ |
| Modality | Cell therapy | “This novel cellular therapy may act as a bridge treatment to liver transplant or lead to regeneration of the native liver.” NCT05491135 ↗ |
| Route | Subcutaneous | “HMB-002 will be administered subcutaneously.” NCT06754852 ↗ |